Anti‐tumor therapies are inherently cytotoxic, and the inability to confine therapeutic effects to the tumor area can lead to severe adverse effects, such as systemic inflammation.[31, 32] Thus, spatiotemporal control of RIG‐I activating oligonucleotides to allow selective activation in the tumor site would be highly beneficial, both in limiting side effects and allowing for higher, local oligonucleotide doses. The gene discussed is RIGI; the disease is neoplasm.